Working... Menu
Trial record 58 of 989 for:    Heparin sodium

Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01072747
Recruitment Status : Unknown
Verified January 2011 by Azidus Brasil.
Recruitment status was:  Recruiting
First Posted : February 22, 2010
Last Update Posted : January 28, 2011
Information provided by:
Azidus Brasil

Brief Summary:
The primary objective of this study is to verify, through a randomized, blinded, parallel clinical trial, the efficacy of bovine heparin from Bergamo Laboratory ACTIPARIN ® product when compared to porcine heparin APP Pharmaceutical in patients undergoing surgery cardiovascular disease and who require cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on measurements of markers of coagulation ACT, aPTT, anti-Xa heparin levels and the excessive blood loss (hemorrhage) after the end of surgery.

Condition or disease Intervention/treatment Phase
Prevention of Venous Thromboembolism Biological: bovine heparin Biological: Porcine heparin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Blind and Comparative Clinical Trial of Efficacy and Security of Unfractioned Heparin Sodium of Bovine Origin in Patients Submitted to Cardiovascular Surgery With Cardiopulmonary Bypass
Study Start Date : April 2010
Estimated Primary Completion Date : August 2011
Estimated Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: heparin of bovine origin
Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
Biological: bovine heparin
5.000UI/mL bottle with 5mL

Active Comparator: heparin of porcine origin
APP Pharmaceuticals
Biological: Porcine heparin
5000 USP Heparin Units / mL vial with 10 mL vial

Primary Outcome Measures :
  1. Coagulometric parameters markers heparin activity: ACT, APTT and Anti - Xa [ Time Frame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative ]

Secondary Outcome Measures :
  1. Value of the total dose of heparin used, the activity and adequate reversal with the use of protamine. [ Time Frame: (T0) Pre heparintion; (T1) Top of extracorporeal; (T2) Intraoperative period; (T3) End bypass; (T4) Postoperative ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who agree with all aspects of the study and sign the FICT;
  • Patients of both sexes;
  • Patients over the age of 18 years;
  • Patients with indication for cardiac surgery requiring cardiopulmonary bypass.

Exclusion Criteria:

  • Patients with hematological disorders that compromise the surgical outcome (eg, myeloproliferative disorders, anemia, Hb <11.0 g / dL, platelets <100,000 mm3);
  • Patients with disorders of hemostasis (INR> 1.40) (APTTr> 1.40);
  • Patients with renal impairment (creatinine> 1.50);
  • Patients with deep hyperthermia;
  • Liver disease (AST and ALT> 2 times that of the reference value);
  • Patients with a history of allergy to heparin or protamine;
  • Patients with a history of heparin-induced thrombocytopenia;
  • infection (eg endocarditis, septicemia and pneumonia);
  • Reoperations;
  • Use of antiplatelet agents (clopidogrel and ticlopidine) for less than 7 days;
  • Use of aspirin for less than 5 days;
  • Use of heparin, low molecular weight less than 24 hours;
  • Use of unfractionated heparin for less than 12 hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01072747

Layout table for location contacts
Contact: Alexandre Frederico, Physician 55 19 3829-3822

Layout table for location information
LAL Clinica Pesquisa e Desenvolvimento Ltda Recruiting
Valinhos, SP, Brazil, 13270000
Contact: Alexandre Frederico, Physician    55 19 3829-3822   
Sponsors and Collaborators
Azidus Brasil

Layout table for additonal information
Responsible Party: Dr. Alexandre Frederico, LAL Clinica Identifier: NCT01072747     History of Changes
Other Study ID Numbers: HEPSBCCV1109BOV_BER
First Posted: February 22, 2010    Key Record Dates
Last Update Posted: January 28, 2011
Last Verified: January 2011

Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium heparin
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action